[Corrections] Correction to Lancet Oncol 2017; 18: 1493–1501

Tawbi HA, Burgess M, Bolejack V, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol 2017; 18: 1493–1501—In this Article (published online on Oct 4, 2017), the Interpretation in the Summary should have read "The primary endpoint of overall response was not met for either cohort. However, pembrolizumab showed encouraging a ctivity in patients with undifferentiated pleomorphic sarcoma or dedifferentiated liposarcoma.

http://ift.tt/2AlAr4o